Efficacy and safety of ginsenoside-Rd for acute ischaemic stroke: A randomized, double-blind, placebo-controlled, phase II multicenter trial

European Journal of Neurology

Volumn 16, Issue 5, 2009, Pages 569-575

  Liu, X ^a   Xia, J ^b   Wang, L ^b   Song, Y ^c   Yang, J ^d   Yan, Y ^e   Ren, H ^f   Zhao, G ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Department of Neurology   (China)

^d LANZHOU GENERAL HOSPITAL   (China)

^e CHONGQING MEDICAL UNIVERSITY   (China)

^f KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Ginsenoside Rd; Ischaemic stroke; Randomized trial

Indexed keywords

GINSENOSIDE RD; PLACEBO;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BARTHEL INDEX; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; HEART INFARCTION; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LIVER DYSFUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VITAL SIGN;

BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; FEMALE; GINSENOSIDES; HUMANS; MALE; MIDDLE AGED; PLACEBOS; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 64149105945     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02534.x     Document Type: Article

References (28)

1. Goldstein LB, Adams R, Alberts MJ, et al. Circulation 2006 113 : 873 923.
2. Dávalos Antoni. Thrombolysis in acute ischemic stroke: successes, failures, and new hopes. Cerebrovascular Disease 2005 20 : 135 139.
3. Hankey GJ. Neuroprotection for acute ischaemic stroke: hope re-ignited. Lancet Neurology 2006 5 : 287 288.
4. Gorelick PB. Neuroprotection in acute ischaemic stroke: a tale for whom the bell tolls? Lancet 2000 355 : 1925 1926.
5. Lees KR, Asplund K, Carolei A, et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 2000 355 : 1949 1954.
6. Muir KW, Lees KR, Ford I, Davis S. Magnesium for acute stroke (intravenous magnesium efficacy in stroke trial): randomized controlled trial. Lancet 2004 363 : 439 445.
7. Jonsson S, Cheng YF, Edenius C, Lees KR, Odergren T, Karlsson MO. Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke. Clinical Pharmacokinetics 2005 44 : 863 878.
8. The Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999 30 : 2752 2758.
9. Turley KR, Toledo-Pereyra LH, Kothari RU. Molecular mechanisms in the pathogenesis and treatment of acute ischemic stroke. Journal of Investigative Surgery 2005 18 : 207 218.
10. 2+ influx through receptor- and store-operated Ca2+ channels in vascular smooth muscle cells. European Journal of Pharmacology 2006 548 : 129 136.
11. Lee JH, Jeong SM, Kim JH, et al. Effects of ginsenosides and their metabolites on voltage-dependent Ca(2+) channel subtypes. Molecules and Cells 2006 21 : 52 62.
12. Yang L, Deng Y, Xu S, Zeng X. In vivo pharmacokinetic and metabolism studies of ginsenoside Rd. Journal of chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2007 854 : 77 84.
13. Meyer BC, Hemmen TM, Jackson CM, Lyden PD. Modified National Institutes of Health Stroke Scale for use in stroke clinical trials: prospective reliability and validity. Stroke 2002 33 : 1261 1266.
14. Hatano S. Experience from a multicenter stroke register: a preliminary report. Bulletin WHO 1976 54 : 541 543.
15. Uyttenboogaart M, Stewart RE, Vroomen PC, De Keyser J, Luijckx GJ. Optimizing cutoff scores for the Barthe index and the modified Rankin scale for defining outcome in acute stroke trials. Stroke 2005 36 : 1984 1987.
16. Adams HP Jr., Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999 53 : 126 131.
17. Rhim H, Kim H, Lee DY, Oh TH, Nah SY. Ginseng and ginsenoside Rg3, a newly identical active ingredient of ginseng, modulate Ca2+ channel currents in rat sensory neurons. European Journal of Pharmacology 2002 463 : 151 158.
18. Blumenthal M. Asian ginseng: potential therapeutic uses. Advance for Nurse Practitioners 2001 2 : 26 28.
19. Radad K, Gille G, Liu L, Rausch WD. Use of ginseng in medicine with emphasis on neurodegenerative disorders. J Pharmacol Sci 2006 100 : 175 186.
20. Mizumaki Y, Kurimoto M, Hirashima Y, et al. Lipophilic fraction of Panax ginseng induces neuronal differentiation of PC12 cells and promotes neuronal survival of rat cortical neurons by protein kinase C-dependent manner. Brain Research 2002 950 : 254 260.
21. Kim S, Ahn K, Oh TH, Nah SY, Rhim H. Inhibitory effect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons. Biochemical and Biophysical Research Communications 2002 296 : 247 254.
22. Zhang B, Hata R, Zhu P, et al. Prevention of ischemic neuronal death by intravenous infusion of a ginseng saponin, ginsenoside Rb(1), that upregulates Bcl-x(L) expression. Journal of Cerebral Blood Flow and Metabolism 2006 26 : 708 721.
23. Shen L, Zhang J. Ginsenoside Rg1 increases ischemia-induced cell proliferation and survival in the dentate gyrus of adult gerbils. Neuroscience Letters 2003 344 : 1 4.
24. Sacco RL, DeRosa JT, Haley EC Jr., et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 2001 285 : 1719 1728.
25. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. New England Journal of Medicine 2006 354 : 588 600.
26. Warach S, Kaufman D, Chiu D, et al. Effect of the glycine antagonist gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI substudy. Cerebrovascular Disease 2006 21 : 106 111.
27. Choi JY, Pary JK, Alexandrov AV, et al. Does clinical-CT 'mismatch' predict early response to treatment with recombinant tissue plasminogen activator? Cerebrovascular Disease 2006 22 : 384 388.
28. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001 32 : 1598 1606.